Bionano Historical Balance Sheet

BNGO Stock

USD 1.11 0.06 5.71%

Trend analysis of Bionano Genomics balance sheet accounts such as Short Long Term Debt Total of 92.3 M, Other Current Liabilities of 8.9 M or Total Current Liabilities of 105 M provides information on Bionano Genomics' total assets, liabilities, and equity, which is the actual value of Bionano Genomics to its prevalent stockholders. By breaking down trends over time using Bionano Genomics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Bionano Genomics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Bionano Genomics is a good buy for the upcoming year.

Bionano Genomics Inventory

24.04 Million

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bionano Genomics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.

To learn how to invest in Bionano Stock, please use our How to Invest in Bionano Genomics guide.

About Bionano Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Bionano Genomics at a specified time, usually calculated after every quarter, six months, or one year. Bionano Genomics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Bionano Genomics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Bionano currently owns. An asset can also be divided into two categories, current and non-current.

Bionano Genomics Balance Sheet Chart

Bionano Genomics Balance Sheet is one of the main financial statements that report all assets, liabilities, and shareholders' equity for the current year. It provides a basis for different types of computing rates of return, such as return on equity (ROE) or return on asset (ROA), as well as shows how Bionano Genomics uses and utilizes its capital. It also shows what exactly a company owns and owes.

At this time, Bionano Genomics' Net Debt is very stable compared to the past year. As of the 23rd of May 2024, Cash is likely to grow to about 55.7 M, while Total Assets are likely to drop about 142.9 M.

Total Assets Short Long Term Debt Total Other Current Liab Total Current Liabilities Inventory

Add Fundamental

Total Assets

Total assets refers to the total amount of Bionano Genomics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Bionano Genomics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Bionano Genomics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Bionano Genomics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most accounts from Bionano Genomics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Bionano Genomics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bionano Genomics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.

To learn how to invest in Bionano Stock, please use our How to Invest in Bionano Genomics guide.At this time, Bionano Genomics' Net Debt is very stable compared to the past year. As of the 23rd of May 2024, Cash is likely to grow to about 55.7 M, while Total Assets are likely to drop about 142.9 M.

	2021	2022	2023	2024 (projected)
Short and Long Term Debt Total	10.7M	11.7M	87.9M	92.3M
Total Assets	377.1M	307.5M	214.4M	142.9M

Short Long Term Debt Total Total Assets

Bionano Genomics balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Long Term Debt	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Long Term Debt Total	Non Current Liabilities Total	Capital Surpluse	Inventory	Other Current Assets	Other Stockholder Equity
Total Assets		0.35	0.64	0.47	0.98	0.79	0.95	0.8	0.84	0.15	-0.67	0.94	0.42	0.95	0.01	0.72	0.96	0.67	0.85	0.86	0.72	-0.35	0.86	0.8	0.91	0.17
Short Long Term Debt Total	0.35		0.04	0.98	0.24	0.78	0.56	0.78	0.42	0.83	-0.91	0.49	0.89	0.31	0.59	0.48	0.3	0.68	0.73	0.76	0.48	-0.39	0.76	0.68	0.48	0.14
Other Current Liab	0.64	0.04		0.23	0.61	0.59	0.45	0.6	0.77	0.21	-0.39	0.68	-0.1	0.82	0.24	0.23	0.45	0.27	0.5	0.53	0.23	0.2	0.51	0.71	0.73	0.38
Total Current Liabilities	0.47	0.98	0.23		0.36	0.88	0.64	0.87	0.54	0.87	-0.95	0.62	0.82	0.47	0.59	0.53	0.39	0.75	0.79	0.83	0.53	-0.35	0.84	0.8	0.6	0.22
Total Stockholder Equity	0.98	0.24	0.61	0.36		0.71	0.92	0.72	0.77	0.01	-0.58	0.89	0.36	0.92	-0.12	0.69	0.96	0.59	0.79	0.79	0.69	-0.4	0.8	0.73	0.85	0.1
Other Liab	0.79	0.78	0.59	0.88	0.71		0.86	1.0	0.82	0.69	-0.95	0.87	0.66	0.81	0.51	0.59	0.68	0.77	0.92	0.97	0.59	-0.3	0.97	0.96	0.86	0.19
Net Tangible Assets	0.95	0.56	0.45	0.64	0.92	0.86		0.86	0.76	0.29	-0.78	0.88	0.64	0.85	0.13	0.72	0.95	0.69	0.91	0.92	0.72	-0.46	0.93	0.8	0.83	0.13
Property Plant And Equipment Net	0.8	0.78	0.6	0.87	0.72	1.0	0.86		0.83	0.66	-0.95	0.88	0.68	0.82	0.49	0.62	0.7	0.76	0.94	0.98	0.62	-0.3	0.97	0.97	0.88	0.24
Current Deferred Revenue	0.84	0.42	0.77	0.54	0.77	0.82	0.76	0.83		0.36	-0.7	0.86	0.37	0.89	0.32	0.55	0.71	0.59	0.77	0.81	0.55	-0.19	0.79	0.85	0.91	0.37
Net Debt	0.15	0.83	0.21	0.87	0.01	0.69	0.29	0.66	0.36		-0.72	0.34	0.48	0.22	0.78	0.13	0.03	0.53	0.44	0.53	0.13	-0.03	0.53	0.61	0.33	0.22
Retained Earnings	-0.67	-0.91	-0.39	-0.95	-0.58	-0.95	-0.78	-0.95	-0.7	-0.72		-0.8	-0.83	-0.68	-0.47	-0.69	-0.57	-0.83	-0.93	-0.95	-0.69	0.43	-0.95	-0.91	-0.8	-0.16
Accounts Payable	0.94	0.49	0.68	0.62	0.89	0.87	0.88	0.88	0.86	0.34	-0.8		0.49	0.96	0.1	0.81	0.83	0.83	0.89	0.9	0.81	-0.38	0.91	0.91	0.98	0.19
Cash	0.42	0.89	-0.1	0.82	0.36	0.66	0.64	0.68	0.37	0.48	-0.83	0.49		0.31	0.29	0.65	0.44	0.63	0.79	0.75	0.65	-0.59	0.75	0.57	0.48	0.03
Non Current Assets Total	0.95	0.31	0.82	0.47	0.92	0.81	0.85	0.82	0.89	0.22	-0.68	0.96	0.31		0.08	0.67	0.83	0.67	0.82	0.84	0.67	-0.27	0.84	0.88	0.96	0.2
Non Currrent Assets Other	0.01	0.59	0.24	0.59	-0.12	0.51	0.13	0.49	0.32	0.78	-0.47	0.1	0.29	0.08		-0.28	-0.07	0.07	0.25	0.35	-0.28	0.41	0.31	0.38	0.15	0.18
Long Term Debt	0.72	0.48	0.23	0.53	0.69	0.59	0.72	0.62	0.55	0.13	-0.69	0.81	0.65	0.67	-0.28		0.68	0.85	0.79	0.72	1.0	-0.7	0.75	0.65	0.77	0.11
Cash And Short Term Investments	0.96	0.3	0.45	0.39	0.96	0.68	0.95	0.7	0.71	0.03	-0.57	0.83	0.44	0.83	-0.07	0.68		0.56	0.78	0.78	0.68	-0.37	0.78	0.64	0.77	0.14
Net Receivables	0.67	0.68	0.27	0.75	0.59	0.77	0.69	0.76	0.59	0.53	-0.83	0.83	0.63	0.67	0.07	0.85	0.56		0.76	0.77	0.85	-0.63	0.82	0.79	0.79	-0.04
Common Stock Total Equity	0.85	0.73	0.5	0.79	0.79	0.92	0.91	0.94	0.77	0.44	-0.93	0.89	0.79	0.82	0.25	0.79	0.78	0.76		0.99	0.79	-0.46	0.98	0.91	0.89	0.21
Common Stock Shares Outstanding	0.86	0.76	0.53	0.83	0.79	0.97	0.92	0.98	0.81	0.53	-0.95	0.9	0.75	0.84	0.35	0.72	0.78	0.77	0.99		0.72	-0.4	0.99	0.94	0.89	0.22
Long Term Debt Total	0.72	0.48	0.23	0.53	0.69	0.59	0.72	0.62	0.55	0.13	-0.69	0.81	0.65	0.67	-0.28	1.0	0.68	0.85	0.79	0.72		-0.7	0.75	0.65	0.77	0.11
Non Current Liabilities Total	-0.35	-0.39	0.2	-0.35	-0.4	-0.3	-0.46	-0.3	-0.19	-0.03	0.43	-0.38	-0.59	-0.27	0.41	-0.7	-0.37	-0.63	-0.46	-0.4	-0.7		-0.47	-0.33	-0.36	0.33
Capital Surpluse	0.86	0.76	0.51	0.84	0.8	0.97	0.93	0.97	0.79	0.53	-0.95	0.91	0.75	0.84	0.31	0.75	0.78	0.82	0.98	0.99	0.75	-0.47		0.94	0.89	0.15
Inventory	0.8	0.68	0.71	0.8	0.73	0.96	0.8	0.97	0.85	0.61	-0.91	0.91	0.57	0.88	0.38	0.65	0.64	0.79	0.91	0.94	0.65	-0.33	0.94		0.93	0.22
Other Current Assets	0.91	0.48	0.73	0.6	0.85	0.86	0.83	0.88	0.91	0.33	-0.8	0.98	0.48	0.96	0.15	0.77	0.77	0.79	0.89	0.89	0.77	-0.36	0.89	0.93		0.19
Other Stockholder Equity	0.17	0.14	0.38	0.22	0.1	0.19	0.13	0.24	0.37	0.22	-0.16	0.19	0.03	0.2	0.18	0.11	0.14	-0.04	0.21	0.22	0.11	0.33	0.15	0.22	0.19

Click cells to compare fundamentals

Bionano Genomics Account Relationship Matchups

Bionano Genomics balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	30.2M	60.4M	377.1M	307.5M	214.4M	142.9M
Short Long Term Debt Total	20.0M	16.3M	10.7M	11.7M	87.9M	92.3M
Other Current Liab	3.2M	5.6M	9.7M	19.9M	8.1M	8.9M
Total Current Liabilities	26.3M	8.9M	21.8M	35.9M	100.0M	105.0M
Total Stockholder Equity	3.6M	35.1M	337.1M	249.4M	96.2M	89.9M
Other Liab	227.1K	97.9K	9.2M	13.1M	15.1M	15.8M
Net Tangible Assets	3.6M	26.4M	337.1M	172.1M	197.9M	207.8M
Property Plant And Equipment Net	1.9M	4.9M	20.9M	29.0M	32.5M	34.1M
Current Deferred Revenue	357.5K	415.5K	684K	871K	783K	555.6K
Net Debt	2.7M	(22.1M)	(13.9M)	6.6M	34.9M	36.6M
Retained Earnings	(102.6M)	(143.7M)	(216.1M)	(348.7M)	(581.2M)	(552.1M)
Accounts Payable	2.7M	2.9M	9.7M	12.5M	10.4M	5.9M
Cash	17.3M	38.4M	24.6M	5.1M	53.1M	55.7M
Non Current Assets Total	1.9M	13.7M	104.7M	150.2M	74.3M	48.6M
Non Currrent Assets Other	(1.9M)	102.6K	749K	2.8M	7.4M	7.8M
Cash And Short Term Investments	17.3M	38.4M	250.6M	113.2M	101.9M	74.8M
Net Receivables	6.3M	2.8M	4.9M	7.0M	9.7M	5.6M
Common Stock Total Equity	3.4K	19.0K	29K	30K	34.5K	36.2K
Common Stock Shares Outstanding	1.5M	10.4M	27.7M	28.9M	34.2M	35.9M
Liabilities And Stockholders Equity	30.3M	60.4M	377.1M	307.5M	214.4M	142.9M
Non Current Liabilities Total	335.0K	16.4M	18.1M	22.2M	18.2M	16.2M
Capital Surpluse	106.2M	178.7M	553.7M	599.2M	689.1M	723.5M
Inventory	3.4M	3.3M	12.4M	29.8M	22.9M	24.0M
Other Current Assets	1.2M	2.2M	4.5M	7.3M	5.7M	3.2M
Other Stockholder Equity	106.2M	178.7M	553.7M	599.2M	677.3M	711.2M
Total Liab	26.6M	25.4M	40.0M	58.1M	118.2M	124.2M
Property Plant And Equipment Gross	1.9M	4.9M	10.3M	29.0M	51.6M	54.1M
Total Current Assets	28.3M	46.8M	272.4M	157.3M	140.1M	94.3M
Non Current Liabilities Other	808.4K	44.5K	18.0M	22.1M	10.9M	8.4M
Common Stock	3.4K	19.0K	29K	30K	5K	4.8K
Property Plant Equipment	1.9M	4.9M	10.3M	18.0M	20.7M	21.8M
Net Invested Capital	23.7M	51.4M	337.1M	249.4M	166.0M	126.2M
Net Working Capital	1.9M	37.8M	250.6M	121.4M	40.1M	72.4M
Retained Earnings Total Equity	(102.6M)	(143.7M)	(216.1M)	(348.7M)	(313.8M)	(298.2M)
Deferred Long Term Liab	182.6K	97.9K	146K	127K	114.3K	137.3K

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Bionano Genomics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bionano Genomics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bionano Genomics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bionano Genomics Stock:

How To Invest In Bionano

Details

Is Bionano Stock a good investment?

Details

What is Bionano Genomics' Net Worth?

Details

Largest Life Sciences Tools & Services Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

To learn how to invest in Bionano Stock, please use our How to Invest in Bionano Genomics guide.

Note that the Bionano Genomics information on this page should be used as a complementary analysis to other Bionano Genomics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.

Complementary Tools for Bionano Stock analysis

When running Bionano Genomics' price analysis, check to measure Bionano Genomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bionano Genomics is operating at the current time. Most of Bionano Genomics' value examination focuses on studying past and present price action to predict the probability of Bionano Genomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bionano Genomics' price. Additionally, you may evaluate how the addition of Bionano Genomics to your portfolios can decrease your overall portfolio volatility.

	Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk
	Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
	Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets
	Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities
	Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities
	Equity Valuation Check real value of public entities based on technical and fundamental data
	Money Managers Screen money managers from public funds and ETFs managed around the world
	Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
	Volatility Analysis Get historical volatility and risk analysis based on latest market data
	Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years
	Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market.

Is Bionano Genomics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bionano Genomics. If investors know Bionano will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bionano Genomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(6.81)

Revenue Per Share

1.058

Quarterly Revenue Growth

0.305

Return On Assets

(0.33)

Return On Equity

(1.35)

The market value of Bionano Genomics is measured differently than its book value, which is the value of Bionano that is recorded on the company's balance sheet. Investors also form their own opinion of Bionano Genomics' value that differs from its market value or its book value, called intrinsic value, which is Bionano Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bionano Genomics' market value can be influenced by many factors that don't directly affect Bionano Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Bionano Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bionano Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bionano Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Bionano Historical Balance Sheet

Bionano Genomics Inventory

24.04 Million

About Bionano Balance Sheet Analysis

Bionano Genomics Balance Sheet Chart

Total Assets

Total Current Liabilities

Bionano Genomics balance sheet Correlations

Bionano Genomics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Bionano Genomics balance sheet Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Bionano Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Property Plant And Equipment Net	+ 1.0	Other Liab
Long Term Debt Total	+ 1.0	Long Term Debt
Common Stock Shares Outstanding	+ 0.99	Common Stock Total Equity
Capital Surpluse	+ 0.99	Common Stock Shares Outstanding
Total Stockholder Equity	+ 0.98	Total Assets
Total Current Liabilities	+ 0.98	Short Long Term Debt Total

Capital Surpluse	- 0.95	Retained Earnings
Common Stock Shares Outstanding	- 0.95	Retained Earnings
Retained Earnings	- 0.95	Property Plant And Equipment Net
Retained Earnings	- 0.95	Other Liab
Retained Earnings	- 0.95	Total Current Liabilities
Common Stock Total Equity	- 0.93	Retained Earnings